Posted on Jul 09, 2018, 5 p.m.
Anti-aging startup Juvenescence recently reeled in a $50 million series A, allowing it to push forward on its core projects and ramp up licensing deals and partnerships, bringing the company’s total to $63 million.
The UK based company is looking to advance longevity therapeutics by creating, investing, or partnering with companies in anti-aging or age related projects, by in-licensing assets from academia and industry, and by forming joint ventures. Financing allows acceleration of licensing and partnership arrangements alongside existing product development and increase development of AI-generated programs.
Juvenescence has a sourced portfolio of therapies they will endeavour to take into clinic in the medium term and others with goals to commercialise in the near term. Juvenescence aims to have 20 shots on the goal of longevity science hoping to get 2-3 off to a good start to produce good returns for shareholders. Spokesperson stated the company is working at record speed to add years of health to life, but did not go into details or specify what the core projects were.
Focused on all aspects of aging, from modifying cellular aging via regeneration to implementing stems cells in regeneration Juvenescence has 2 drugs being worked on through preclinical trials that are being prepared for IND, and another 8 under letter of intent which they hope to move forward with in the near future as preclinical.
This company is not the only one looking to tackle human aging. California based Unity Biotechnology recently gained a $55 million series C and has filed to raise $85 million in its IPO, capital which will set the company to move 2 drugs into human testing of its lead program UBX0101 which is an inhibitor of MDm2-p53 protein interaction about to start testing in osteoarthritis patients; and UBX1978 an inhibitor of certain Bcl-2 apoptosis regulatory proteins will enter clinic next year.
Materials provided by:
Note: Content may be edited for style and length.